Medscape1d
Study Indicates Who May Benefit Most From GA Treatment
A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.
What's Going With Apellis Pharmaceuticals Stock Friday?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...
Zacks.com on MSN1d
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
Apellis Pharmaceuticals APLS announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Medscape4d
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...
Pharmaceutical Technology on MSN11d
Sobi and Enable Injections partner for Aspaveli distribution
Sobi and Enable Injections have entered an agreement for the development and distribution of Aspaveli in combination with ...
Apellis eye drug again turned back in Europe
The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple ...
Apellis: CHMP Once Again Recommends Against Syfovre
The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...
Pharmabiz11d
Sobi, Enable Injections ink agreement to develop and distribute Aspaveli in combination with enFuse in Sobi territories
Sobi, Enable Injections ink agreement to develop and distribute Aspaveli in combination with enFuse in Sobi territories: Sweden Saturday, September 14, 2024, 10:00 Hrs [IST] Sobi, ...